OverviewSuggest Edit

Smith & Nephew is a medical technology company. It operates in three main segments: Orthopaedic Reconstruction and Trauma, Endoscopy and Advanced Wound Management. The company offers sports medicine joint repair products for surgeons, arthroscopic enabling technologies for healthcare providers, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, electromechanical and mechanical tissue resection devices, etc. 

TypePublic
Founded1856
HQUS
Websitesmith-nephew.com
Overall CultureB

Latest Updates

Employees (est.) (Dec 2017)15,000
Job Openings355
Revenue (FY, 2018)£3.7 B(+3%)
Share Price (Nov 2020)£15 (-2%)
Cybersecurity ratingCMore

Key People/Management at Smith & Nephew

Olivier Bohuon

Olivier Bohuon

CEO
Graham Baker

Graham Baker

Chief Financial Officer
Dave Illingworth

Dave Illingworth

Chief Executive Officer
Roland Diggelmann

Roland Diggelmann

Chief Executive Officer
Vinita Bali

Vinita Bali

Independent Non-Executive Director
Adrian Hennah

Adrian Hennah

Chief Financial Officer
Show more

Smith & Nephew Office Locations

Smith & Nephew has offices in Andover, Austin, Durham, Fort Worth and in 2 other locations
São Paulo, BR
Av. do Café, 277
Andover, US
150 Minuteman Rd
Austin, US
7000 W William Cannon Dr
Durham, US
Carlisle Place, 4721 Emperor Blvd #100
Fort Worth, US
3909 Hulen St
Saint Petersburg, US
970 Lake Carillon Dr #110
Show all (7)

Smith & Nephew Financials and Metrics

Smith & Nephew Revenue

Embed Graph
View revenue for all periods
Smith & Nephew's revenue was reported to be £3.72 b in FY, 2018 which is a 2.9% increase from the previous period.
GBP

Revenue (FY, 2018)

3.7b

Revenue growth (FY, 2017 - FY, 2018), %

2.9%

Gross profit (FY, 2018)

2.7b

Gross profit margin (FY, 2018), %

73.5%

Net income (FY, 2018)

502.7m

EBITDA (FY, 2018)

838.6m

EBIT (FY, 2018)

654.4m

Market capitalization (13-Nov-2020)

13.1b

Closing stock price (13-Nov-2020)

15.0

Cash (31-Dec-2018)

276.8m

EV

12.9b
Smith & Nephew's current market capitalization is £13.1 b.
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.1b1.0b1.1b1.1b1.1b1.1b1.1b1.2b1.2b1.4b1.4b2.0b2.9b3.2b3.6b3.4b3.6b3.7b

Revenue growth, %

(2%)1%6%1%(5%)3%6%6%13%1%43%11%13%(5%)7%3%

Cost of goods sold

472.6m446.1m453.3m479.6m456.8m350.2m329.9m345.1m334.8m361.0m1.1b600.7m724.8m797.5m883.4m923.3m946.3m984.2m

Gross profit

596.6m602.0m600.1m640.3m677.9m731.5m780.0m833.8m913.7m1.0b292.0m1.4b2.1b2.4b2.7b2.5b2.7b2.7b
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

80.5m57.1m49.9m100.5m24.6m30.0m22.5m26.0m32.6m88.0m177.0m102.7m90.3m63.8m92.8m72.6m128.1m276.8m

Accounts Receivable

218.7m219.9m233.1m241.8m246.2m224.4m222.6m246.0m273.5m323.0m322.0m468.3m616.1m664.3m751.3m717.2m800.7m837.1m

Inventories

229.8m225.7m242.4m237.6m228.2m232.2m229.5m230.6m284.9m355.0m316.0m504.0m662.8m810.5m940.6m903.0m988.8m1.1b

Current Assets

564.5m561.3m570.9m619.2m530.6m525.4m532.7m591.1m679.3m937.0m840.0m1.2b1.5b1.7b1.9b1.8b2.1b2.3b
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

120.7m113.7m93.7m104.8m205.2m129.6m112.1m148.1m125.2m170.0m201.0m191.0m366.3m343.8m316.9m569.1m581.6m502.7m

Cash From Operating Activities

189.3m181.7m161.9m198.1m204.0m191.9m209.3m214.5m226.6m147.0m190.0m264.7m571.3m468.7m796.1m616.3m826.5m705.9m

Dividends Paid

66.5m69.0m69.2m72.5m456.9m42.9m44.6m46.1m47.8m50.0m49.0m62.8m157.5m164.0m202.5m195.3m

Cash From Financing Activities

40.4m(19.7m)158.7m17.8m94.8m(93.1m)(16.9m)(22.0m)(196.0m)209.7m(328.1m)691.8m(431.3m)(384.0m)(329.1m)(281.3m)
GBPFY, 1996

Financial Leverage

1.9 x
Show all financial metrics

Smith & Nephew Operating Metrics

Smith & Nephew's Training Provided, no. of people was reported to be 90 k in FY, 2016.
FY, 2016

Training Provided, no. of people

90 k
Show all operating metrics

Smith & Nephew Acquisitions / Subsidiaries

Company NameDateDeal Size
Integra LifeSciencesSeptember 29, 2020$240 m
Osiris TherapeuticsMarch 15, 2019$600 m

Smith & Nephew Revenue Breakdown

Embed Graph

Smith & Nephew revenue breakdown by business segment: 12.9% from Sports Medicine Joint Repair , 13.9% from Arthroscopic Enabling Technologies , 9.9% from Trauma & Extremities, 19.8% from Knee Implants, 12.9% from Hip Implants, 14.9% from Advanced Wound Care, 6.9% from Advanced Wound Bioactives and 8.9% from Other

Smith & Nephew Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Smith & Nephew Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Smith & Nephew Online and Social Media Presence

Embed Graph

Smith & Nephew Company Culture

  • Overall Culture

    B

    69/100

  • CEO Rating

    A

    75/100

  • Compensation

    A+

    85/100

  • Diversity

    B+

    74/100

Learn more on Comparably

Smith & Nephew News and Updates

North America Artificial Joints Market is estimated to grow by escalating at a CAGR during the forecast period 2027| Key Players Smith & Nephew, Stryker Corporation, Zimmer Biomet

An artificial joint is a device used in orthopedic surgery procedures in which an arthritic or dysfunctional joint surface is surgically replaced. They are also called prostheses and designed to enable improved joint function and correct abnormalities associated with joint movement. Artificial joint…

Smith & Nephew buying Integra LifeSciences unit

Smith & Nephew said it's buying the extremity orthopedics unit of Integra LifeSciences for $240 million in cash. Smith & Nephew said the deal will provide entry into the shoulder replacement and foot and ankle segment. The business generated revenue of $90 million in 2019 and traded at a …

Smith & Nephew spies recovery despite falling sales

Medical technology firm Smith & Nephew said it expects to slowly recover from the impact of the coronavirus pandemic, as The post Smith & Nephew spies recovery despite falling sales appeared first on CityAM.

London Markets: Smith & Nephew stands out in otherwise struggling London stock market

London stocks struggled for direction on Thursday, as investors assessed fresh coronavirus risk, with Smith & Nephew PLC standing out with gains after upbeat results.

Emerging markets help Smith & Nephew beat annual sales record

Improved underlying revenue growth of 4.4 per cent has propelled Smith & Nephew’s sales above $5bn (£3.8bn) for the first [...] The post Emerging markets help Smith & Nephew beat annual sales record appeared first on CityAM.

Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc

COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris t…
Show more

Smith & Nephew Frequently Asked Questions

  • When was Smith & Nephew founded?

    Smith & Nephew was founded in 1856.

  • Who are Smith & Nephew key executives?

    Smith & Nephew's key executives are Olivier Bohuon, Graham Baker and Dave Illingworth.

  • How many employees does Smith & Nephew have?

    Smith & Nephew has 15,000 employees.

  • What is Smith & Nephew revenue?

    Latest Smith & Nephew annual revenue is £3.7 b.

  • What is Smith & Nephew revenue per employee?

    Latest Smith & Nephew revenue per employee is £247.9 k.

  • Who are Smith & Nephew competitors?

    Competitors of Smith & Nephew include Zimmer Biomet, Integer Holdings and Stryker.

  • Where are Smith & Nephew offices?

    Smith & Nephew has offices in Andover, Austin, Durham, Fort Worth and in 2 other locations.

  • How many offices does Smith & Nephew have?

    Smith & Nephew has 7 offices.